

Board and management members of Panion Animal Health AB (publ), subscribes for shares in the current emission

Panion Animal Health AB ("Panion") is currently offering existing shareholders and others the rights to subscribe for shares in the emission running from 16 – 30 May 2018. The Board of Panion has decided the issue with preference for existing shareholders of a total of approximately SEK 9.2 million.

http://panion-animalhealth.com/emisson/

Earlier this week, the CEO of Panion, Anja Holm, announced that she will subscribe for 100.000 SEK in the emission. Now the board members in Panion, Lars Friis Mikkelsen and Dede Willis, the Chief Financial Officer Sofia Josephson, and the Business Development Director Carlos Velez announce that they will also subscribe for shares in the current emission.

Anja Holm says: "I am very pleased with that, because it reflects the dedication and confidence that the members of the management and board have in our progress and prospect, which is very reassuring. We all work hard to move the project forward and we invest competence, qualifications, time, and money, because we want to succeed. With the recent good news from CombiGene on EU-funding, we believe in a fast development that will also benefit Panion's work."

Subscription period 16 May - 30 May 2018 Subscription price 1,14 SEK per share



Anja Holm, CEO, Panion Animal Health AB

 $This press \ release \ contains \ information \ which \ Panion \ Animal \ Health \ AB \ is \ obliged \ to \ publish \ according \ to \ the \ EU \ market \ abuse \ regulation \ (MAR).$ $This \ information \ was \ submitted \ by \ Panion's \ CEO, \ Anja \ E. \ H. \ Holm, \ for \ publication \ on \ May \ 28 \ 2018.$

For further information, please contact:

Ánja E. H. Holm, CEO | +45-22 94 66 00 anja.holm@panion-animalhealth.com

Developing animal health – In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at AktieTorget.

Panion Animal Health AB

Frykholmsgatan 11, 281 31 Hässleholm, Sweden info@panion-animalhealth.com

linkedin.com/company/panion-animalhealth



panion-animalhealth.com/newsletter



